Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

Summary

Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3% cream over a 6-week treatment period compared to its vehicle.

Timeline

Start

2016-11-01

Primary completion

2017-06-26

Completion

2017-06-26

Outcome

Missed primary endpoint

registry analysis (superiority test); CD5024 0.3% Cream vs Placebo; p = 0.632; Least Square (LS) Mean Difference -0.28 (95% CI -1.46 to 0.89); ANCOVA NCT03250624 ↗

Drugs

Indications